Study: A Randomized Double Blind Phase II Study of Dabrafenib and Trametinib With or Without Hydroxychloroquine in Advanced BRAF V600E/K Melanoma With Elevated LDH
Enrolling By Invitation
18 years - 80 years
All
Phase
N/A
10 participants needed
1 Location
Brief description of study
This phase II trial investigates how well adding hydroxychloroquine to the standard treatment of dabrafenib and trametinib works to overcome resistance and delay disease progression in treating patients with stage IIIC or IV BRAF V600E/K melanoma. Giving hydroxychloroquine together with dabrafenib and trametinib may work better than dabrafenib and trametinib alone to shrink and stabilize the cancer.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Melanoma,melanoma
-
Age: 18 years - 80 years
-
Gender: All
Male or Female at least 18 years of age. stage IV melanoma.
Updated on
04 Aug 2024.
Study ID: 848765
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245
